PErsonalized Addition of Recombinant LH in Ovarian Stimulation

Recruiting Phase 4 Interventional Study
Infertility
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
35 – 40
Sex
Female
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
120 (estimated)
Sponsor
Fundación Santiago Dexeus Font · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Different ovarian stimulation regimens have shown to modify late follicular phase hormonal profiles. Besides, recent studies confirm that progesterone levels and their variation in the last day of oocyte maturation are affected by the dose of gonadotropins administered and by other factors. Progesterone elevation in late follicular phase of in vitro fertilization/intracytoplasmatic sperm injection…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Able and willing to sign the Patient Consent Form and adhere to study visitation schedule. * ≥ 35 years ≤40 years old. * AFC ≥5 and or AMH ≥1.2 ng/mL. * \<4 or 4-9 oocytes retrieved in a previous IVF/ICSI cycle with a starting dose of ≤225 IU with any gonadotropin under a GnRH…
Contacts

Nikolaos P Polyzos, MD PhD

0034932274700

nikpol@dexeus.com

CONTACT

Ignacio Rodríguez, MSc

0034932274700

nacrod@dexeus.com

CONTACT